Microbiome-wide characterization of post-translational modifications

Kai Cheng[1], Zhibin Ning[1], Xu Zhang[1], Janice Mayne[1] and Daniel Figeys[1,2]*

*Correspondence: dfigeys@uottawa.ca

[1]Department of Biochemistry, Microbiology and Immunology, Ottawa Institute of Systems Biology and Shanghai Institute of Materia Medica-University of Ottawa Joint Center in Systems and Personalized Pharmacology, Faculty of Medicine, University of Ottawa, Ontario, Canada

[2]Molecular Architecture of Life Program, Canadian Institute for Advanced Research, Toronto, Ontario, Canada.

Studying the structure and function of microbiomes is an emerging research field. Metaproteomic approaches focusing on the characterization of expressed proteins and post-translational modifications (PTM) provide deeper understanding of microbial communities. Previous research has highlighted the value of examining microbiome-wide protein expression in studying the roles of the microbiome in human diseases. Nevertheless, regulation of protein functions in complex microbiomes remains under-explored. This is mainly due to the lack of efficient bioinformatics tools to identify and quantify PTMs in the microbiome. Here we implemented an unrestricted open search strategy and developed an advanced multistage post-validation workflow for the identification of PTMs with high accuracy and sensitivity. This approach is applicable to proteomic and metaproteomic datasets. For metaproteomics, this method was combined into a complete data post-analysis workflow, including a quantitative module, to provide a novel and comprehensive data processing platform for metaproteomic analysis. This bioinformatics platform provides information about proteins, PTMs, taxa, functions, and pathways of microbial communities. The performance of the workflow was evaluated using conventional proteomics, metaproteomics from mouse and human gut microbiomes, and modification-specific enriched datasets.

The relationship between the microbiome and human health has been a very active subject of

research in recent years[1, 2].   The study of host-microbiome relationships has been primarily focused

on the composition of the microbial community and the relative abundance of microbes using DNA

sequencing-based technologies, as well as functions of the microbiome using metagenomics and

metatranscriptomics[3]. Metaproteomics provides direct assessments of the microbiome functions by

qualitative and quantitative investigating the expressed proteins products[4], [5-8]. Post-translational

modifications (PTM), which are important for the dynamic regulations of the biological functions of

the microbiome, can also be identified by mass spectrometry based metaproteomics[9]. Yet,

characterization of the PTM profile from microbial communities bring additional computational

challenges in data interpretation. Conventional protein identification strategies allow a few

pre-selected PTMs to be identified (variable modifications) but are not suitable to identify multiple

modifications and unknown modifications. In contrast, open search strategies allow unbiased

identification of potential PTMs and amino acid variants[10]. Unfortunately, the application of open

search strategies in metaproteomics has been limited. Open search strategies increase the search

space when considering multiple possible mass differences for modified peptides. This is

compounded for metaproteomics as protein sequence databases are already very large. Generally,

an increase of several hundred-fold in processing time occurs during open searches. Fortunately,

several recently developed software tools have significantly improved open search speeds[11, 12],

making open search feasible on a metaproteomic scale. Nevertheless, considering the complexity of

microbial communities, ensuring the accuracy of peptide and PTM identifications is difficult. Several

hundred potential PTMs can be found from one metaproteomic dataset. Calculation of the false

discovery rate (FDR) at the peptide spectra match (PSM) level provides only an overall estimation of

the confidence of identified peptides.

To address this challenge, we developed a multistage filtering strategy for the evaluation of open

search results. A series of strict filtering criteria were applied for PTM, PSM, peptide and protein

levels, which significantly improved the sensitivity and accuracy of the open search results. Since

quantitative analysis is an indispensable step in proteomic data processing workflows, we

incorporated a quantitative tool, FlashLFQ[13] into our pipeline. By combining this tool with our

previously developed taxonomy analysis and functional annotation modules[14, 15], we built a complete

workflow, which enables researchers to study the profile of PTMs of microbiota samples, as well as

relationships with taxa, functions and pathways. Moreover, traditional proteomic studies using single

species are certainly supported by this strategy. This software is free for academic use and has a

user-friendly Graphic User Interface (GUI). Both online and local versions of the tool are available at

https://imetalab.ca/.

RESULTS AND DISCUSSION

Tackling the problem of false discovery rate control with a multistage filtering strategy

The validation of peptide identification is a tricky problem in proteomics. The most prevalent strategy

for validation of methods in proteomic software is the use of a target-decoy database search, which

provides an estimate of the probability of random matches. Generally a FDR cutoff at 1% is accepted,

however, it has been proposed that a lower FDR threshold (of about 0.1%) is required for open

search results, which would ensure a comparable confidence level with the conventional closed

search strategy[16]. Moreover, only controlling the FDR at the PSM level is not sufficient for the

investigation of PTMs.

Herein we developed a multistage filtering strategy for the confident identification of peptides and

PTMs using open search (**Figure 1**). Briefly, first the MS/MS spectra were searched against a

target-decoy database by open search. Then PSMs were binned according to their mass deviations

(ΔMass) (**Figure 2a**). The ΔMass peaks were detected by Gaussian fitting analysis through the whole

ΔMass range. The PSMs that did not belong to any ΔMass peaks were filtered out. Then for each

Gaussian peak the R^2 was calculated and only peaks with R^2 above 0.9 were retained. The centroid of

each peak was also determined during the curve fitting step, which was the experimental mass shift

of the potential modification. Noting that the causes for the mass shift are various, including PTM,

amino acid substitution, chemical derivative etc., they are all termed as "potential modifications".

Usually in closed searches the precursor mass tolerance is set as 10 ppm. Therefore, in this step, the

PSMs with ΔMass from the centroid of the corresponding Gaussian peak exceeding 10 ppm were

discarded.

We first used a previously reported HEK293 data set[10] for demonstration. After the PSM list was

obtained and the Gaussian peaks along the ΔMass range were fitted, we investigated the score

distribution of the four types of PSMs: unmodified target PSMs (PSMs belonged to the Gaussian peak

located at ΔMass=0, annotated as "peak 0"); target PSMs belonged to any other Gaussian peaks than

the "peak 0" ("peak other"), for example, the 4 peaks annotated in **Figure 2a**; target PSMs outside of

any Gaussian peaks ("no peak"); and all of the decoy PSMs ("decoy") (**Figure 2b**). Overall the

unmodified target PSMs were assigned with higher scores. The difference between "peak other" and

"no peak" was major. However, the medians of "no peak" and "decoy" were quite close. This result

showed that PSMs that didn't belong to any ΔMass peak were more inclined to be random matches.

It was observed that PSMs that belonged to the fitted Gaussian peaks had higher scores than the

PSMs outside of the Gaussian peaks (**Figure 2c-m**). For this dataset, 44.7% (463,673/1,038,110) PSMs

didn't belong to any Gaussian peaks. After this portion was removed, a FDR of about 1.1%

(6,268/568,169) was obtained from the remaining PSMs. In this step 207 ΔMass peaks were kept,

among which 160 peaks were identified as monoisotopic peptide peaks (**Online Methods**). As a

result, aside from the peak with ΔMass of 0 representing unmodified peptides, 159 types of potential

modifications were obtained. To further validate the result, we compared it with the closed search

result. In the closed search 46,868 decoy PSMs were obtained in total, with 10,236 of the same

spectra also identified as decoy matches in open search (**Supplementary Fig. 1**). This portion can

represent random matches. We found these decoy matches were generally distributed evenly in the

ΔMass range (about 10% were concentrated in ΔMass=0 because unmodified peptides had higher

priority). In the filtering step 84.2% (8,619/10,236) of them were removed because they didn't

belong to any ΔMass peak. This result proved that retaining only those PSMs belonging to high

quality Gaussian peaks in the ΔMass range can effectively eliminate random matches. We also found

that of 36,480 decoy PSMs in the closed search that matched to target sequences and that were

assigned with higher scores, 46.5% (16,969/36,480) of them contained potential modifications which

were determined in the previous step. Among the 16,969 PSMs assigned with potential

modifications and higher scores, 6,601 PSMs were found with the potential modification

ΔMass=1.0036, which should be the first isotopic peak. These results showed that the portion of

modified peptides identified incorrectly in closed searches can be recovered by an open search

strategy, improving the sensitivity of the analysis.

After the first filtering step the FDR was 1.1%, but it should be noted that if we calculated the

modification-specific FDR, that is using the PSMs within a certain ΔMass Gaussian peak to calculate

the FDR of this group, the FDRs were below 1% for only 12 potential modifications (**Supplementary**

Fig. 2). The FDR of the unmodified peptides which accounted for 80.2% (460,546/574,437) of the

total amount of PSMs was only 0.28% (1,290/460,546). This meant that the FDR was higher for the

modified portion. Only controlling the FDR at the level of PSM cannot assure the confidence of PSMs

with certain modifications. Therefore, we added filtering at the level of modification. Firstly a

classification score was assigned to each PSM based on a semi-supervised machine learning

strategy[17] (**Online Methods**, **Supplementary Table 1**). Then for each potential modification, an

unpaired two-sample t-test was performed between target PSMs and decoy PSMs using the assigned

classification score. If the two sets of score values showed significant difference (*p*-value < 0.01), this

modification was retained. Following this step, 17 ΔMass peaks were discarded. The remaining

modifications were considered "true" with PSMs having significant differences between target and

decoy matches.

The last filtering process was adopted at the protein and peptide levels. The protein inference

algorithm was utilized at this step to calculate the scores of the proteins and peptides[18]. Then the

protein and peptide lists were filtered to ensure that, at both levels, the FDRs were less than 1%. For

this dataset the final FDRs were only 0.08% (441/562,302) at the PSM level and 0.15% (179/120,037)

at the peptide level, respectively (**Supplementary Data 1**). In total 142 possible modifications were

detected, with 50 modifications matched with items in Unimod (http://www.unimod.org/) and 40

unknown modifications that can be constructed by combining two modifications from the 50 known

modifications (**Supplementary Table 2**). We analyzed the compositions of 40 unknown modifications

and found that 72% (29/40) of them contained at least one modification listed below: -156.1019,

156.1014, 128.0951 and -128.0958 Da, which corresponded to addition/loss of Arg or Lys. Loss of the

terminal amino acid by in-source fragmentation was common in ESI-MS. Addition of Arg or Lys could

be caused by additional missed cleavage sites (consecutive Arg or Lys in the peptide C-term). In

addition, 25% (10/40) of the combinations contained -71.0375 Da (Gln->Gly), -71.0743 Da (Lys->Gly)

or -57.0221 Da (Asn->Gly/Gln->Ala), which were related to amino acid substitutions. Therefore, from

the combination of information we can determine that potential modifications without Unimod

matched items, can be explained by known modifications to a large extent.

In summary, we applied this method to a large scale proteomic dataset from the HEK293 cell line.

The results illustrated that high confident identifications at all of the four levels (PSMs, peptides,

proteins and potential modifications) were obtained. Compared with conventional database search

methods, the sensitivity was significantly improved by our strategy (**Supplementary Fig. 3a**). Using

this strategy 562,302 PSMs were identified with PSM level FDR<0.08%, and peptide and protein level

FDR<1%. In a closed search in which even the peptide and protein level FDR were not considered,

434,526 PSMs were obtained with PSM level FDR<1%. If we continued to restrict the FDR at the

peptide and protein levels to 1%, 385,990 PSMs remain (**Supplementary Fig. 3b**). The significant

improvement of sensitivity using our strategy was not only because of the identification of modified

peptides, which cannot be identified in the conventional method; in fact, the 459,367 unmodified

PSMs obtained in open search were more than the number obtained in closed search. With proper

filtering, the increased search space did not sacrifice the identification sensitivity; on the contrary, it

improved it. The first reason was 36.2% (16,969/46,868) decoy PSMs were matched to more credible

targets. This portion of loss was recovered in open search, at the same time the additional expense

for the elimination of these random matches in FDR control was avoided. The second reason was

that random matches were basically evenly distributed over a wider range, which made the ΔMass a

significant feature to distinguish random matches effectively. Based on these reasons we developed

the post-analysis workflow for the analysis of open search datasets, which showed greatly improved

accuracy and sensitivity of identifications.

Identification of a group of phosphorylation related modifications from enriched samples

To further benchmark the post-validation strategy, we re-analyzed *E. coli* phospho-enriched samples

(Dataset ID: Ecoli_phos)[19] to measure the proportion of PSMs that could be identified as

phosphopeptides. Authenticating our strategy, phosphorylation was identified as the most abundant

modification from the phospho-enriched *E. coli* sample. Even more substantiating, the 2nd-4th

potential modifications were phosphate-ribosylation (ΔMass=212.0091), PhosphoHex

(ΔMass=242.0195) and 3-phosphoglyceryl (ΔMass=167.983), respectively, which were all

phosphorylation related modifications. Actually, by manual interpretation of the spectra from the top

30 abundant mass differences, we found that neutral loss of phosphorylation was observed from 14

types of potential modifications (**Supplementary Data 2, Supplementary Material 1**). Aside from

phosphorylation, pyrophosphorylation (ΔMass=159.9328), and the abundant phospho-related

modifications mentioned above, other known phospho-related modifications also include

phosphogluconoylation (ΔMass=258.0149) and pyridoxal phosphate (ΔMass=229.0134). No Unimod

records were found for possible modifications with experimental ΔMass 151.9878. We inferred the

composition as H(5)C(3)O(5)P because according to the ΔMass it is most likely deducting one oxygen

from 3-phosphoglyceryl. We also inferred the composition of ΔMass 181.9985 as H(7)C(4)O(6)P(1),

because the mass difference between this and 3-phosphoglyceryl is 14.0154 Da which could be a

methylene group. The possible structures of the identified phospho-related modifications were

illustrated (**Figure 3a**).

Phosphate-ribosylation is a tag of ADP-Ribosylation, which is a versatile PTM involved in various

cellular processes[20, 21]. It has been reported that ADP-Ribosylation sites could be detected in

phosphoproteomics data by setting it as the corresponding variable modification during database

searches[22]. In this dataset phosphate-ribosylation were identified as the 2nd most frequent PSM

count. In theory, the ADP-ribose group can be attached on multiple amino acids, such as Asp, Glu, Lys,

Arg and Cys. The specificity sites for phosphate-ribosylation recorded in Unimod are Asp, Glu and Arg.

However, in this dataset, the modification sites were observed as Lys and protein N-term. In total,

86.3% (864/1001) of phosphate-ribosylation modified peptides contain a missed cleavage site Lys.

Additionally, 7.4% (74/1001) of peptides start with the first amino acid of the proteins, and 8.9%

(89/1001) of peptides start with the second amino acid of the proteins, for a total of 16.3%

(163/1029) peptides containing protein N-term (**Supplementary Material 1**). Through the functional

enrichment analysis of the proteins with phosphate-ribosylation sites, 61 biological processes with

FDR below 0.05 were obtained (**Figure 3b, Supplementary Table 3, 4**). The colored three biological

processes were all branches of nucleoside phosphate metabolic process, which suggested the

important role of ADP-ribosylation in this process. The 3rd and 4th potential modifications were

matched with PhosphoHex and 3-phosphoglyceryl, respectively. As above, most phosphoHex and

3-phosphoglyceryl modified peptides contained a missed cleavage site (Lys) or protein N-term. The

manually annotated spectra showed that the modifications occurred on the Lys at the missed

cleavage site or protein N-term (**Supplementary material 1**). These results clearly showed the

advantage of open search for the identification of coexisting PTMs from enriched samples. For

example, Lys and protein N-term were not specified sites of phosphate-ribosylation and phosphoHex

in Unimod, so these sites would be missed when setting these as variable modifications in closed

searches. However, in open searches, novel modifications or known modifications on novel sites can

be readily identified. The proteome-wide investigation of phosphate-ribosylation sites and their

abundance is important for the further understanding of ADP-ribosylation functions.

Encouraged by this success we investigated phosphorylation enriched mammalian samples from

mouse kidney (Dataset ID: Mouse_phos)[23]. Surprisingly, only two of the top 30 ΔMasses were

matched with known modifications in Unimod, namely phosphorylation and pyrophosphorylation

(**Supplementary Data 3**). It's easy to find ΔMasses 239.8978 and 319.8637 that represented multiple

phosphorylation sites occurring on one peptide. By manually interpretation of the spectra we found

that all of the unknown ΔMasses were combinations of multiple modifications, and in most cases,

were combinations of phosphorylation and others (**Supplementary material 2**). In fact, among the

top 30 abundant ΔMasses, 26 contained at least one phosphate group, which strongly confirmed the

confidence of this result. Four of them were combinations of phosphorylation and cations (protons

replaced by Na^+ or K^+). This type was not observed for *Ecoli*_phos (but common in mouse_phos).

While 3-phosphoglyceryl and phosphate-ribosylation were found with few PSMs counts and

phosphoHex was not observed. Apart from this, peptides from mouse_phos tended to contain

multiple modifications, which was a significant difference between these two datasets.

We also studied two human cell lines, HeLa[24] (Dataset ID: Hela_phos, **Supplementary Data 4,**

Supplementary material 3) and U-87 glioblastoma cells (Dataset ID: U87_phos, **Supplementary Data**

5, Supplementary material 4)[25]. Similar to the mouse_phos dataset, multiple phosphorylation and

combinations of phosphorylation and other modifications were prevalent. But complex

phospho-related modifications as these existed in *Ecoli*_phos data were very rarely observed. Our

results clearly showed the different features of phosphopeptides identified from bacteria and

mammal cells. In *Ecoli*_phos the majority of peptides have only one modification, including some

complex modification forms and unknown modifications. From the mammalian datasets, multiple

phosphorylation sites on one peptide were common rather than phospho-related complex

modifications. At the same time, peptides modified by cations were often observed from mammalian

datasets, but rare in *Ecoli*_phos datasets. Using our strategy co-enriched modifications can be

identified in one step which is of great significance for the analysis of interactions of different

modifications. Collectively, these results showed significant benefits of the application of open

searches for enriched sample analyses.

Identifying the modification profile from microbiome samples

We also applied our workflow to analyze a microbiome dataset which was constructed by assembling

32 species/strains of Archaea, Bacteria, Eukaryotes and Bacteriophages[26] (**Supplementary Note,**

Supplementary Data 6). Given the advantage of known microbial composition in this dataset, we

also used this dataset to benchmark the quantitative accuracy of our method, to investigate if the

quantitation will be affected by the additionally identified peptides from open search. In total, we

identified 1,048,759 PSMs, which was 16% more than from conventional closed searches

(**Supplementary Fig. 4**). Through quantitative analysis of the mock microbiota community,

satisfactory quantitative accuracy was obtained at the species-level, which also confirmed the

confidence of the identifications of modified peptides (**Supplementary Fig. 5**, **Supplementary Note**).

To demonstrate the capability of open searches for microbiome sample analyses we applied the

developed strategy to analyze a mouse gut microbiome dataset (Dataset ID: Mouse_gut)[27]. In total

918,132 PSMs were identified with an estimated FDR of 0.17%. The PSM count increased

significantly by 28.3%, 202,682 additional PSMs were identified when compared with our previous

work [14]. At the peptide level the FDR is 0.33% and 127,218 unique sequences (37,544 peptides

contained at least one modified form) were obtained (**Supplementary Data 7**). In closed search

115,832 peptide identifications were obtained and so the open search strategy resulted in a 9.8%

increase in peptide identifications (**Figure 4a**). For the commonly identified portion, most of the

peptides were only identified as unmodified in the open search, but there were about 20% peptides

that contained at least one modified form. For the additional identified portion by open search,

about 40% of peptides were found only in modified forms and over 50% were unmodified. This result

showed that, not only was the missing information of modified peptides retrieved from the open

search, but also, that the improved sensitivity of the workflow enabled the additional detection of

unmodified peptides. The increase in the number of confidently recognized species (with at least

three unique peptides) was also realized. In this work 172 species were identified containing equal or

more than three unique peptides. The number was 143 from the previous work, with a major

common portion of 134 species shared by the two results (**Figure 4b**). The 29 species identified only

in this workflow were illustrated and their distribution at the phylum level was shown in **Figure 4b**.

Most of the newly found species were from phyla *Firmicutes* and *Bacteroidetes*. Actually, 27 species

were also identified using the conventional method but without enough unique peptide counts,

which also showed the confidence of the species specifically determined using the new strategy.

From this result we can conclude that through our strategy, comparable accuracy and optimized

sensitivity can be obtained by open searches when compared with traditional closed searches for the

analysis of real microbiota samples.

In this experiment the mouse gut microbiome were collected from both high-fat diet (HFD) and

low-fat diet (LFD) fed mice for the interpretation of diet-microbiota-host interactions[27]. In this work,

based on the quantitative information of the potential modifications, we investigated the response

of the determined modifications to diet in mouse microbiomes. The abundances of various

modifications were calculated in each identified taxon node. Both the absolute and relative values

were considered, that is, for each taxon the summation of the intensity of peptides with specific

modifications were calculated as the absolute abundance of the modification in this taxon, and the

ratio between the absolute value and the total abundance of this taxon were calculated as the

relative abundance. Firstly, we tested if there were modifications that showed significant differences

between HFD and LFD. We found that the modification ΔMass=71.0368 (Acrylamide adduct/Gly->Gln

substitution) showed significant increases in the HFD samples using both absolute and relative values,

and the modification ΔMass=52.1229 (replacement of 3 protons by iron) decreased significantly in

relative value (**Figure 5a, Supplementary material 5**). This result confirmed the ability of our strategy

for the identification of quantitative changes of PTMs from real gut microbiome samples.

Since there were two possibilities for the modification ΔMass=71.0368, we investigated the

information of localization sites to determine which was validate. Acrylamide adducts may occur on

Cys, Lys and any amino acid on peptide N-term whereas Gly->Gln substitution only exists on Gly.

Considering all the possible sites for localization analysis, we found Lys the most frequent

modification site for ΔMass=71.0368 (**Supplementary Fig.6**), which suggested that the most

probable modification was an acrylamide adduct. The relative abundance of modified peptides in

each taxonomy in both HFD and LFD samples were illustrated respectively (**Figure 5b**). The

compositions and relative abundances were almost constant in these two conditions. The lineage

Bacteria->Firmicutes->Bacilli->Lactobacillales->Streptococcaceae->Lactococcus->Lactococcus lactis

was the main source for acrylamide adduct modifications and contributed to the high abundance in

HFD samples directly. At the protein level the difference was derived from the single site K264 from

protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in *Lactococcus lactis*. GAPDH is

involved in the glucose metabolic process and related to the function NAD binding, NADP binding

and GAPDH (NAD+) (phosphorylating) activity. Acrylamide adducts have been deemed as potentially

toxic compounds in food[28]. The degradation of acrylamide by bacteria was widely studied[29, 30] and

Bacillus cereus has been reported to efficiently degrade acrylamide[31]. Molecular mechanisms of the

addition of acrylamide adducts on GAPDH was studied by incubating purified human GAPDH with

acrylamide and the kinetics of Cys acrylamide adduct formation was characterized, but the

modification on Lys was not described[32]. This work presented the novel discovery of Lys acrylamide

adducts on GAPDH from *Lactococcus lactis*, and the potential relationship with HFDs.

For the modification replacement of three protons by iron (cation:Fe[III] for short), the most

abundant species were *Bacteroides vulgatus* and *Parabacteroides goldsteinii* from the same order

Bacteroidales (**Figure 5c**). Significant change was only observed in species *Parabacteroides goldsteinii*.

The involved proteins included TonB-dependent receptor, RagB/SusD family nutrient uptake outer

membrane protein, SusC/RagA family TonB-linked outer membrane protein and hypothetical

proteins. The first three were all membrane proteins and TonB-dependent receptor was a known iron

transporter[33]. The identification of cation:Fe[III] modification on these proteins could help

researchers further their understanding of the transport mechanism of bacteria.

Identification of multiple types of glycosylation from human gut microbiome dataset

We then applied this workflow for the analysis of a human gut microbiome dataset from a study

about type 1 diabetes (Dataset ID: Human_gut)[34]. Two subject groups of data from healthy control

(CO, n=22) and new-onset patients (NO, n=33) were analyzed. From this dataset we identified

829,458 PSMs at FDR about 0.16% (**Supplementary Data 8**). Only 676,282 PSMs were obtained at

the FDR about 4.1% by the conventional method (**Supplementary Fig. 7**). The identification rate was

increased from 35.8% to 44.0%, and while a much lower FDR was obtained. For each sample, 10,305

± 2,205 (mean ± standard deviation) unique peptide sequences and 4,763 ± 1,027 proteins were

quantified. In total 43,475 non-human microbiome proteins and 629 human proteins were identified.

We quantified 611 species, among which 240 species were identified with more than three unique

peptides. Annotations with KEGG database allowed us to identify 459 ± 69 microbial and 100 ± 27

human KEGG orthologies (KOs) per sample.

Here we identified 288 types of potential modifications and 102 were successfully matched to

records in Unimod. Those known modifications covered 82% (78,931/97,102) of the modified PSMs.

In general, human proteins had more PTMs than microbial proteins (**Supplementary Fig. 8**). PSMs

from human proteins accounting for 17.7% (146,734/829,458) of the total number but contributed

to 41.8% (40,608/97,102) of the PSMs with PTMs. The dynamic range of various modifications was

high. The top 10 modifications covered 56.6% of the total number of modified PSMs identified in this

study (**Supplementary Fig. 9**).

Currently the glycosylation in the microbial community is an under-studied area. For a better

understanding of the gut microbiome-host interactions the characterization of glycosylation is

absolutely necessary. In this study, five types of glycosylation including Hex (hexose, ΔMass =

162.053), HexNAc (N-Acetylhexosamine, ΔMass = 203.079), HexNAc1dHex1 (ΔMass = 349.137),

HexNAc2 (ΔMass = 406.159) and bacillosamine (2,4-diacetamido-2,4,6-trideoxyglucopyranose,

ΔMass = 228.1110) were identified from this dataset (**Figure 6a**). An important feature of the

glycopeptide spectra were that the diagnostic ions could be observed in low mass-to-charge ratios

(m/z), which were called glycan oxonium ions[35]. In our results, we detected at least one glycan

oxonium ion whose intensity exceeded 50% of the peaks in the corresponding MS2 spectra, in 92.0%

(5,424/5,895), 94.6% (5,750/6,078), 93.4% (157/168) and 69.5% (91/131) of the HexNAc,

HexNAc1dHex1, HexNAc2, and bacillosamine modified PSMs, respectively (**Supplementary Table 5**).

Manual verifications were also adopted for part of the glycopeptide spectra, and generally

successive y-ions were observed in these spectra (**Supplementary material 6**). These results ensured

the reliability of the identification of glycopeptides. Interestingly, we found the distributions of these

glycosylations between human and microbial proteins differed. Two types of glycosylation with

apparently higher abundances, HexNAc1dHex1 and HexNAc were only observed on human proteins.

For Hex and HexNAc2, there were 38.1% (45/118) and 28.6% (48/168) of the PSMs that were

identified from microbial proteins, respectively. Bacillosamine was a rare monosaccharide which was

found in bacterial glycoproteins[36]. And in our results 93.1% (122/131) of the bacillosamine modified

PSMs were from bacteria proteins.

Glycosylation plays a critical role in the regulation of protein functions. The alterations of

glycosylation could affect the immune system of mammals[37]. The relationship between abnormal

glycosylation and the pathogenesis of diabetes has also been reported[38]. In this dataset, significant

decreases in the abundance of HexNAc modified peptides were detected in NO patients compared

to CO subjects (**Figure 6b**). Functional enrichment analysis of HexNAc modified proteins was

performed (**Figure 6c, Supplementary Table 6**). Neutrophil related immune response was the most

significantly enriched biological processes (**Supplementary Fig. 10**). Among the enriched Gene

Ontology (GO) terms, nine of them were significantly changed (**Supplementary Fig. 11**). Five of them

(transport, response to stress, inflammatory response, response to stimulus and localization) were

also downregulated in NO samples which were consistent with the general trend. But four catabolic

processes (catabolic process, cellular catabolic process, organonitrogen compound catabolic process

and organic substance catabolic process) related functions were upregulated.

Besides high abundant human protein glycosylation, we also identified three types of glycosylation

from microbial proteins. For hexose, 21 glycopeptides were identified, only one peptide was from

Bacteroidetes and 16 peptides were from *Firmicutes* (**Supplementary Fig. 12, Supplementary table**

7). In this dataset, 86.7% (39/45) of the hexose modified PSMs were from *Clostridiales*. From the

functional annotation, we found that the most frequently observed function related to hexose was

ABC-type glycerol-3-phosphate transport system, periplasmic component (**Figure 6d**). For HexNAc2,

one peptide EAATTAAAAAATTDVADKK was identified from eight CO and seven NO samples,

respectively, which was the most widely identified glycopeptide from bacteria in Human_gut

(**Supplementary Fig. 13, Supplementary table 7**). The lowest common ancestor (LCA) of this peptide

was *Clostridia* (order level). The corresponding protein was ABC-type sugar transport system,

periplasmic component, contains N-terminal xre family HTH domain, which was also an ATP-binding

cassette (ABC) transporter. It could be seen that the ABC transporter families were the most

frequently identified glycoproteins from bacteria in Human_gut. We also identified bacteria specific

monosaccharide Bacillosamine from 48 glycopeptides. Bacillosamine was described as an

"Asn-linked glycan from Gram-negative Bacterium" in Unimod. However, we noticed that only 45.8%

(22/48) glycopeptides contained Asn, which suggested the existence of other types such as O-linked

glycopeptides in these samples. Bacillosamine was involved in various functions in this dataset

(**Supplementary Table 7**). We identified the LCA for 21 glycopeptides (**Supplementary Fig. 14**). Three

peptides determined in superkingdom level as bacteria were from the protein Elongation factor Tu

(EF-Tu), which was a highly conserved proteins in prokaryotes. EF-Tu was a type of GTPase, which

was also an important antibiotic target[39]. For the remainder of the glycopeptides, seven were from

Bacteroidetes and eight were from Firmicutes. The main COG categories were carbohydrate

transport and metabolism (G) and energy production and conversion (C). The characterization of

bacteria glycosylation will greatly improve our understanding of gut microbiome-host interactions.

Conclusion

Modifications of peptides bring mass variations which can increase the number of unidentified

spectra in traditional database searches. The open search strategy is a method capable of identifying

modifications in an unrestricted manner, however, the validation of the results remains challenging,

especially for the studies of microbial communities. To address this, we developed a multistage

filtering strategy, which could ensure the confidence of the results at various levels: PSMs, peptides,

proteins and modifications. In this method, rigorous filters are utilized to remove potential

modifications with less confidence. The analysis of the benchmark datasets (Homo_HEK293,

Mock_micro, Mouse_gut and Human_gut) suggests that high accuracy is achieved without the

sacrifice of sensitivity. It is worth noting that the identification rates are greatly improved in the

analysis of complex mouse/human gut microbiota samples using open search strategy. Combined

with the previously developed metaproteomics data analysis tools by our group, a novel

bioinformatics workflow is provided for the comprehensive analysis of PTM profiles from microbial

communities. Rich and quantitative information can be obtained easily and with high accuracy, which

is the major reason we recommend this strategy to be a standard workflow for

proteomics/metaproteomics studies.

Figures

Figure 1.

Workflow of the post-analysis processes of open search datasets. After the open search result was obtained, in steps 2-5 a multi-stage filtering strategy was adopted for the results validation. Then MS1 intensity-based label free quantification was performed. The final step was taxonomy analysis and functional annotation for metaproteomics studies. This workflow is also suited for the analysis of conventional proteomics datasets.

Figure 2.

(a) The density of ΔMass distribution of the identified PSMs. The zoomed-in part shows four ΔMass peaks which were detected by Gaussian fitting along the ΔMass range. (b-m) Score distributions of PSMs identified by open search. The score was calculated as $-Log_{10}(Expect)$ and higher scores represented better matches. (b) Peak 0: the scores of the PSMs in the fitted Gaussian peak on the position ΔMass=0, which consisted of PSMs without modifications; Peak other: the PSMs in other fitted Gaussian peaks than Peak 0, which consisted of modified PSMs; No peak: the scores of the PSMs with modifications but do not belong to any ΔMass peaks; Decoy: the scores of all the decoy PSMs. (c) first box: the scores of the PSMs with ΔMass from -0.07 to -0.02. -0.07 was the right edge of a Gaussian peak and -0.02 was the left edge of the next Gaussian peak, therefore the PSMs in this range did not belong to any Gaussian peak; second box: the scores of the PSMs with ΔMass from -0.02 to 0.02. -0.02 and 0.02 were the left and right edges of a fitted Gaussian peak respectively, which consisted of unmodified PSMs; third box: the scores of the PSMs with ΔMass from 0.02 to 0.09. 0.09 was the left edge of the next Gaussian peak, so the PSMs in this range also do not belong to any Gaussian peak; fourth box: the scores of the decoy PSMs with ΔMass from -0.07 to 0.09. (d-m) examples of the scores of the PSMs with other potential modifications. Similarly, the first box represented the scores of the PSMs between this Gaussian peak and the previous Gaussian peak; the second box represented the scores of the PSMs belong to this Gaussian peak; the third box represented the scores of the PSMs between this Gaussian peak and the next Gaussian peak; the fourth box represented the scores of all the decoy PSMs in this range.

Figure 3.

Phospho-related modifications identified from phosphorylation enriched *E.coli* samples. (a) Possible structures and the corresponding PSM counts of phospho-related modifications; (b) network and enriched biological process of proteins with phosphate-ribosylation modifications.

Figure 4.

The comparison of the identified (a) peptides and (b) species by closed search and open search from

434   mouse gut microbiota samples.

Figure 5.

436   **(a)** The absolute and relative abundances of potential modifications ΔMass=71.0368 and
437   ΔMass=52.1229 identified in mouse gut microbiome. **(b-c)** The relative abundance of each taxon
438   determined by **(b)** acrylamide adduct and **(c)** cation:Fe[III] modified peptides in HFD and LFD
439   samples.

Figure 6.

(a) Identified potential modifications and their distribution between human and microbial proteins.
Purple dots: modifications matched in Unimod; Grey dots: unknown modifications. The annotated
modifications fulfilled one of the following two conditions: 1) with above 1,000 PSM counts; 2) with
above 100 PSM counts and more than 90% were from microbial proteins. The possible structures of
five glycosylation were illustrated. **(b)** HexNAc modified glycopeptides showed significant difference
between CO and NO samples. **(c)** The enriched biological process of HexNAc modified human
glycoproteins. **(d-e)** The functions of the microbial proteins modified by **(d)** Hex and **(e)** HexNAc. CO:
control subjects; NO; new-onset patients.
449

Methods

Workflow

This strategy has been incorporated into our previously developed metaproteomics data analysis software MetaLab (version 2.0.0). Only mass spectrometer raw files and searched protein databases were required as the input. The input raw files were converted to mzXML and MGF format for the post analysis. The converted mzXML files were subject to MSFragger (version 20171106) for the peptide identification. Carboxyamidomethylation on C was set as fixed modification. Although an open search can identify modifications unrestrictedly, considering that oxidation on Met and acetylation on protein N-term commonly exist, these two were still set as variable modification. Oxidation and acetylation that occur on other amino acids would be identified by open search. The precursor mass tolerance was set as 500 Da and the fragment mass tolerance was set as 10 ppm. A target-decoy database was utilized for the FDR estimation.

After the identification results were obtained, all the PSMs were binned according to the determined ΔMass. Through the ΔMass range, the Gaussian peaks with R^2 above 0.9 were detected (users can change this parameter in our software). PSMs don't belong to any ΔMass Gaussian peak were discarded. The centroids of the fitted Gaussian peaks were determined. For each PSM, the mass of their potential modification was set as the mass of the calculated centroid, instead of the mass deviation determined directly from the open search result. If the relative mass difference between the original mass deviation and the calculated centroid was above 10 ppm, this PSM was also discarded. After the mass of the modification of each PSM was determined, deisotoping was performed. The theory mass difference between two isotope peaks was set as 1.00286864 Da[40]. When we found two Gaussian peaks, $Peak_i$ ($\Delta Mass=M_i$) and $Peak_j$ ($\Delta Mass=M_j$), which fulfilled the conditions that $|M_j-M_i-1.00286864|\leq0.01$, and at the same time $Peak_i$ had more PSMs than $Peak_j$, $Peak_j$ was deemed as an isotope peak of $Peak_i$. The mass of modifications of PSMs in $Peak_j$ was set as M_i in this step.

Then a semi-supervised machine learning strategy was performed (**Supplementary Table 1**). The 10% top scored PSMs were randomly distributed into five datasets, and all the decoy PSMs were

appended to each of the datasets for the construction of training datasets. Five naive Bayes

classifiers were built based on the training datasets and used to calculate the probability for each

PSM to be a target/decoy one. A classification score was assigned for each PSM, which was

calculated by the average of the probabilities to be a target match determined by the five classifiers.

Then the PSMs were sorted by the newly assigned classification score, and the top 10% were

selected for another loop of the classification. After five iterations, the average of the probabilities

were determined as the final classification score.

The next step was filtering PSMs at the modification level. Unpaired t-tests were performed between

the classification scores of target and decoy PSMs. We also created a universal decoy sample which

consisted of the classification scores of all the decoy PSMs. For each of the modifications, if there

were significant differences (p-value<0.01) between the classification scores of target PSMs and

decoy PSMs, and at the same time, between the target PSMs and the universal decoy PSMs, this

modification was deemed as validated. Modifications which did not satisfy any of the two conditions

were filtered out.

The final step of the multi-stage strategy was performing filtering at all of the three levels: protein,

peptide and PSM. A protein inference algorithm was adopted for this step[18]. Then according to the

determined protein and peptide scores, the FDRs were controlled at less than 1% for all of the three

levels. Usually the protein level FDR was about 1% and the other levels much less than 1%.

According to the filtered PSMs, MS1 peak intensity based label free quantitation was adopted[13].

Then the qualitative and quantitative information of PSMs, peptides, proteins and modifications

were exported. For conventional proteomics studies the post analysis workflow ended here. For

metaproteomic studies, taxonomy analysis and functional annotation were then performed

consecutively[14, 15].

Benchmark dataset

The information of the analyzed benchmark dataset was as follows. For each dataset refer to the

corresponding supplementary data for the detailed information about the raw files used, the

identified potential modifications, PSMs, peptides and proteins. Some examples of manually

annotated spectra of PSMs with most frequently identified modifications (usually the top 30) were

provided for four datasets, including *Ecoli*_phos (**Supplementary Material 1**), Mouse_phos

(**Supplementary Material 2**), Hela_phos (**Supplementary Material 3**), U87_phos (**Supplementary**

Material 4). Examples of manually annotated spectra of glycopeptides were provided for Human_gut

dataset (**Supplementary Material 5**).

Dataset ID	Supplementary Data ID	PRIDE id	Species	Tissues/Cell	Enrichment information	Raw file count
Homo_HEK293[10]	1	PXD001468	Homo sapiens	HEK293	-	32
Ecoli_phos[19]	2	PXD008289	Escherichia coli	-	Phosphorylation	9
Mouse_phos[23]	3	PXD001792	Mus musculus	Kidney	Phosphorylation	6
Hela_phos[24]	4	PXD004940	Homo sapiens	HeLa	Phosphorylation	6
U87_phos[25]	5	PXD009227	Homo sapiens	U-87 glioblastoma cells	Phosphorylation	24
Mock_micro[26]	6	PXD006118	Mock microbiome	-	-	24
Mouse_gut[27]	7	PXD003527	Mouse gut microbial community	-	-	32
Human_gut[34]	8	PXD008870	Human gut microbial community	-	-	55

Functional enrichment analysis

The functional enrichment analysis was performed with STRING (https://string-db.org, version

11.0)[41]. For the analysis of the functions of phosphate-ribosylation modified proteins in *Ecoli*_phos,

proteins with above 50 PSM counts were used.

Acknowledgement

This work was supported by the Government of Canada through Genome Canada and the Ontario

Genomics Institute (OGI-114), CIHR grant (ECD-144627), the Natural Sciences and Engineering

Research Council of Canada (NSERC, grant no. 210034), the Ontario Ministry of Economic

Development and Innovation (REG1-4450) and The University of Ottawa.

References

1.   Knight, R. et al. The Microbiome and Human Biology. *Annu Rev Genom Hum G* 18, 65-86 (2017).

2.   Gilbert, J.A. et al. Current understanding of the human microbiome. *Nat Med* 24, 392-400 (2018).

3.   Knight, R. et al. Best practices for analysing microbiomes. *Nat Rev Microbiol* 16, 410-422 (2018).

4.   White, R.A., Callister, S.J., Moore, R.J., Baker, E.S. & Jansson, J.K. The past, present and future of
microbiome analyses. *Nat. Protoc.* 11, 4-8 (2016).

5.   Zhang, X. et al. Metaproteomics reveals associations between microbiome and intestinal
extracellular vesicle proteins in pediatric inflammatory bowel disease. *Nat Commun* 9 (2018).

6.   Xiong, W.L., Giannone, R.J., Morowitz, M.J., Banfield, J.F. & Hettich, R.L. Development of an
Enhanced Metaproteomic Approach for Deepening the Microbiome Characterization of the Human
Infant Gut. *J Proteome Res* 14, 133-141 (2015).

7.   Maier, T.V. et al. Impact of Dietary Resistant Starch on the Human Gut Microbiome, Metaproteome,
and Metabolome. *Mbio* 8 (2017).

8.   Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases.
Nature 569, 655-662 (2019).

9.   Zhang, W.P. et al. Post-translational modifications are enriched within protein functional groups
important to bacterial adaptation within a deep-sea hydrothermal vent environment. *Microbiome* 4
(2016).

10.   Chick, J.M. et al. A mass-tolerant database search identifies a large proportion of unassigned
spectra in shotgun proteomics as modified peptides. *Nat. Biotechnol.* 33, 743-749 (2015).

11.   Kong, A.T., Leprevost, F.V., Avtonomov, D.M., Mellacheruvu, D. & Nesvizhskii, A.I. MSFragger:
ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. *Nat*
Methods 14, 513-520 (2017).

12.   Chi, H. et al. Comprehensive identification of peptides in tandem mass spectra using an efficient
open search engine. *Nat. Biotechnol.* 36, 1059-+ (2018).

13.   Millikin, R.J., Solntsev, S.K., Shortreed, M.R. & Smith, L.M. Ultrafast Peptide Label-Free
Quantification with FlashLFQ. *J Proteome Res* 17, 386-391 (2018).

14.   Cheng, K. et al. MetaLab: an automated pipeline for metaproteomic data analysis. *Microbiome* 5,
157 (2017).

15.   Liao, B. et al. iMetaLab 1.0: a web platform for metaproteomics data analysis. *Bioinformatics* 34,
3954-3956 (2018).

16.   Li, D.H. et al. Optimal Settings of Mass Spectrometry Open Search Strategy for Higher Confidence. *J
Proteome Res* 17, 3719-3729 (2018).

17.   Kall, L., Canterbury, J.D., Weston, J., Noble, W.S. & MacCoss, M.J. Semi-supervised learning for
peptide identification from shotgun proteomics datasets. *Nat. Methods* 4, 923-925 (2007).

18.   Uszkoreit, J. et al. PIA: An Intuitive Protein Inference Engine with a Web-Based User Interface. *J
Proteome Res* 14, 2988-2997 (2015).

19.   Potel, C.M., Lin, M.H., Heck, A.J.R. & Lemeer, S. Defeating major contaminants in Fe(3+)-IMAC
phosphopeptide enrichment. *Mol Cell Proteomics* (2018).

20.   Bock, F.J., Todorova, T.T. & Chang, P. The Promise of Proteomics for the Study of ADP-Ribosylation.
Mol Cell 58, 911-924 (2015).

21.   Luscher, B. et al. ADP-Ribosylation, a Multifaceted Posttranslational Modification Involved in the
Control of Cell Physiology in Health and Disease. *Chem. Rev.* 118, 216-260 (2018).

22.   Matic, I., Ahel, I. & Hay, R.T. Reanalysis of phosphoproteomics data uncovers ADP-ribosylation sites.
Nat. Methods 9, 771-772 (2012).

23.   Humphrey, S.J., Azimifar, S.B. & Mann, M. High-throughput phosphoproteomics reveals in vivo
insulin signaling dynamics. *Nat. Biotechnol.* 33, 990-U142 (2015).

24.   Espadas, G., Borras, E., Chiva, C. & Sabido, E. Evaluation of different peptide fragmentation types
and mass analyzers in data-dependent methods using an Orbitrap Fusion Lumos Tribrid mass
spectrometer. *Proteomics* 17 (2017).

25.   Humphrey, S.J., Karayel, O., James, D.E. & Mann, M. High-throughput and high-sensitivity
phosphoproteomics with the EasyPhos platform. *Nat. Protoc.* 13 (2018).

26.   Kleiner, M. et al. Assessing species biomass contributions in microbial communities via
metaproteomics. *Nat Commun* 8 (2017).

27.   Zhang, X. et al. MetaPro-IQ: a universal metaproteomic approach to studying human and mouse gut
microbiota. *Microbiome* 4 (2016).

28.　Friedman, M. Acrylamide: inhibition of formation in processed food and mitigation of toxicity in
cells, animals, and humans. *Food Funct* 6, 1752-1772 (2015).

29.　Nawaz, M.S., Franklin, W. & Cerniglia, C.E. Degradation of Acrylamide by Immobilized Cells of a
Pseudomonas Sp and Xanthomonas-Maltophilia. *Can J Microbiol* 39, 207-212 (1993).

30.　Wyatt, J.M. & Knowles, C.J. Microbial-Degradation of Acrylonitrile Waste Effluents - the
Degradation of Effluents and Condensates from the Manufacture of Acrylonitrile. *Int Biodeter*
Biodegr 35, 227-248 (1995).

31.　Shukor, M.Y. et al. Isolation and characterization of an acrylamide-degrading Bacillus cereus. *J*
Environ Biol 30, 57-64 (2009).

32.　Martyniuk, C.J. et al. Molecular Mechanism of Glyceraldehyde-3-phosphate Dehydrogenase
Inactivation by alpha,beta-Unsaturated Carbonyl Derivatives. *Chem Res Toxicol* 24, 2302-2311
(2011).

33.　Noinaj, N., Guillier, M., Barnard, T.J. & Buchanan, S.K. TonB-Dependent Transporters: Regulation,
Structure, and Function. *Annual Review of Microbiology, Vol 64, 2010* 64, 43-60 (2010).

34.　Gavin, P.G. et al. Intestinal Metaproteomics Reveals Host-Microbiota Interactions in Subjects at Risk
for Type 1 Diabetes. *Diabetes Care* 41, 2178-2186 (2018).

35.　Eshghi, S.T. et al. Classification of Tandem Mass Spectra for Identification of N- and O-linked
Glycopeptides. *Sci Rep-Uk* 6 (2016).

36.　Young, N.M. et al. Structure of the N-linked glycan present on multiple glycoproteins in the
gram-negative bacterium, Campylobacter jejuni. *J Biol Chem* 277, 42530-42539 (2002).

37.　Marth, J.D. & Grewal, P.K. Mammalian glycosylation in immunity. *Nat Rev Immunol* 8, 874-887
(2008).

38.　Bermingham, M.L. et al. N-Glycan Profile and Kidney Disease in Type 1 Diabetes. *Diabetes Care* 41,
79-87 (2018).

39.　Parmeggiani, A. & Nissen, P. Elongation factor Tu-targeted antibiotics: Four different structures,
two mechanisms of action. *Febs Lett* 580, 4576-4581 (2006).

40.　Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range
mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* 26, 1367-1372 (2008).

41.　Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated over the tree of
life. *Nucleic Acids Res.* 43, D447-D452 (2015).

1. Open search result

2. Filtering PSMs based on ΔMass

ΔMass

Feature extraction

Training model

Classification

3. Semi-supervised machine learning based classification

Score   Score

4. Filtering ΔMass peaks by t-test

Proteins	Peptides	PSMs

FDR <1%

5. Controlling FDR in PSM, peptide and protein levels

Abundance

Retention time

6. MS1 intensity-based label free quantification

7. Taxonomy analysis and functional annotation

a

* modification on protein n-term which lose the first amino acid Met, so the actual ΔMass is 20.9481 + 131.0405 = 151.9886.
# modification on Cys (fixed modification site by Carbamidomethyl in database search), so the actual ΔMass is 22.945 + 57.0215 = 79.9665.

b

#term ID	term description
GO:1901566	organonitrogen compound biosynthetic process
GO:0006096	glycolytic process
GO:0046496	nicotinamide nucleotide metabolic process
GO:1901564	organonitrogen compound metabolic process
GO:0046394	carboxylic acid biosynthetic process
GO:0044283	small molecule biosynthetic process
GO:0044249	cellular biosynthetic process
GO:1901576	organic substance biosynthetic process
GO:0009168	purine ribonucleoside monophosphate biosynthetic process
GO:0017144	drug metabolic process
GO:0006732	coenzyme metabolic process
GO:0044237	cellular metabolic process
GO:0009987	cellular process
GO:0043603	cellular amide metabolic process
GO:0008152	metabolic process
GO:0006412	translation
GO:0043604	amide biosynthetic process
GO:0019693	ribose phosphate metabolic process
GO:0009108	coenzyme biosynthetic process

a

17,091
11.8%

98,741
68.4%

28,477
19.7%

Closed search

Open search

20,044

78,243

1,966

11,621

14,890

■ Both ■ Only unmodified ■ Only modified

b

Closed search

9
5.2%

134
77.9%

29
16.9%

Open search

Christensenella minuta
Treponema phagedenis
Clostridium kluyveri
Clostridioides difficile
Clostridia bacterium BRH_c25
[Clostridium] neopropionicum
[Clostridium] clariflavum
Cloacibacillus porcorum
Tyzzerella nexilis
Bacteroides xylanisolvens
Pelosinus fermentans
Ruminococcus sp. SR1/5
Treponema succinifaciens
[Clostridium] methylpentosum
Sebaldella termitidis
Clostridium sp. (strain ATCC 29733 / VPI C48-50)
Clostridium aceticum
Clostridium stercorarium
Alistipes putredinis
Slackia heliotrinireducens
Bacteroides helcogenes
Pseudobacteroides cellulosolvens
[Clostridium] hiranonis
[Clostridium] cellulosi
Parabacteroides sp. YL27
Candidatus Moduliflexus flocculans
Bacteroides sp. D22
Thermobacillus composti
Coprobacillus sp. 29_1

Additionally identified
species in phylum level

Spirochaetes 7%

Fusobacteria 4%

Synergistetes 3%

Actinobacteria 4%

Bacteroidetes 18%

Firmicutes 64%

a

Log(PSM count)

Ratio (microbial/total)

HexNAc1dHex1 HexNAc
HexNAc2 Hexose
Cation:Fe[II]
Carbamidomethyl
Acetald+26
Ammonium
Ammonia-loss
Deamidation
Oxidation
Lys
Methyl
Methylol
Glu->Asp
Tyr->Phe
Lys->Gln
Amidated
Bacillosamine

Gln->Gly
Gly->Gln
NIPCAM
Glu
Xlink:EGS[115]
Dicarbamidomethyl
Met-loss
Arg->Tyr
Ser->Pro

b

P = 0.048

CO   NO

c

GO-term	Description	Count in gene set	False discovery rate
GO:0002283	neutrophil activation involved in immune response	32 of 489	5.96E-22
GO:0002446	neutrophil mediated immunity	32 of 498	5.96E-22
GO:0043312	neutrophil degranulation	31 of 485	1.06E-21
GO:0002366	leukocyte activation involved in immune response	33 of 616	4.09E-21
GO:0045055	regulated exocytosis	34 of 691	7.65E-21
GO:0045321	leukocyte activation	36 of 894	1.61E-19
GO:0002252	immune effector process	36 of 927	4.48E-19
GO:0046903	secretion	36 of 1070	3.77E-17
GO:0002376	immune system process	50 of 2370	9.78E-17
GO:0006955	immune response	40 of 1560	2.04E-15
GO:0016192	vesicle-mediated transport	40 of 1699	3.45E-14
GO:0006508	proteolysis	34 of 1203	6.35E-14
GO:0050435	amyloid-beta metabolic process	7 of 16	2.13E-09
GO:0035333	Notch receptor processing, ligand-dependent	6 of 7	2.93E-09
GO:0016485	protein processing	12 of 142	3.21E-09
GO:1901564	organonitrogen compound metabolic process	61 of 5281	3.25E-09
GO:0006810	transport	52 of 4130	1.42E-08
GO:0002682	regulation of immune system process	29 of 1391	1.59E-08
GO:0043603	cellular amide metabolic process	21 of 732	3.29E-08
GO:0051179	localization	57 of 5233	2.38E-07

d

Uncharacterized surface anchored protein

ABC-type sugar transport system, periplasmic component, contains N-terminal xre family HTH domain

Formyltetrahydrofolate synthetase

Major membrane immunogen, membrane-anchored lipoprotein

ABC-type glycerol-3-phosphate transport system, periplasmic component

Alpha-tubulin suppressor and related RCC1 domain-containing proteins

Basic membrane lipoprotein Med, periplasmic binding protein (PBP1-ABC) superfamily

Flagellin and related hook-associated protein FlgL

Aconitase A

L-fucose mutarotase/ribose pyranase, RbsD/FucU family

CO
NO

0   20

PSM count

e

DNA-binding transcriptional regulator, LacI/PurR family

L-fucose isomerase or related protein

Glycine/serine hydroxymethyltransferase

ABC-type sugar transport system, periplasmic component, contains N-terminal xre family HTH domain

Cysteine synthase

Molecular chaperone DnaK (HSP70)

Ribosome-associated translation inhibitor RaiA

ABC-type glycerol-3-phosphate transport system, periplasmic component

CO
NO

0   40

PSM count